Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director · President & CEO | August 21, 2026 | August 25, 2026 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,619,792 |
Ending reported balance
After 2026-08-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-21 · Sale · Disposed 15,009 · Balance 1,663,357 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 15,976 · Balance 1,647,381 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 8,411 · Balance 1,638,970 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 19,178 · Balance 1,619,792 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 24,364 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 24,364 F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 1,000 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,000 F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.
Tempest Therapeutics, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26 | Direct | 1,230 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 25, 2026 23:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 19,178 | $3.86 | $73,967.63 |
DisclosureSEC source: 0001321402-26-000019 · wk-form4_1787699234.xml · nonDerivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,619,792 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 8,411 | $3.86 | $32,440.39 |
DisclosureSEC source: 0001321402-26-000019 · wk-form4_1787699234.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,638,970 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 15,976 | $3.86 | $61,617.83 |
DisclosureSEC source: 0001321402-26-000019 · wk-form4_1787699234.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647,381 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 15,009 | $3.86 | $57,888.21 |
DisclosureSEC source: 0001321402-26-000019 · wk-form4_1787699234.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,663,357 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,834 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001321402-26-000016 · wk-form4_1784318944.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,834 Underlying: Common Stock · 20,834 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,668 | $5.06 | $210,923.42 |
DisclosureSEC source: 0001321402-26-000016 · wk-form4_1784318944.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,678,366 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.03 to $5.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,834 | $0.99 | $20,625.66 |
DisclosureSEC source: 0001321402-26-000016 · wk-form4_1784318944.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,720,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001321402-26-000014 · wk-form4_1781726515.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,668 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,666 | $5.67 | $236,346.22 |
DisclosureSEC source: 0001321402-26-000014 · wk-form4_1781726515.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,699,200 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.625 to $5.77, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,833 | $0.99 | $20,624.67 |
DisclosureSEC source: 0001321402-26-000014 · wk-form4_1781726515.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,740,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 14,028 | $6.27 | $87,920.49 |
DisclosureSEC source: 0001321402-26-000012 · wk-form4_1779480361.xml · nonDerivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,720,033 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 17,926 | $6.27 | $112,351.21 |
DisclosureSEC source: 0001321402-26-000012 · wk-form4_1779480361.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,734,061 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,861 | $6.27 | $49,268.82 |
DisclosureSEC source: 0001321402-26-000012 · wk-form4_1779480361.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,751,987 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 14,933 | $6.27 | $93,592.58 |
DisclosureSEC source: 0001321402-26-000012 · wk-form4_1779480361.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,759,848 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001321402-26-000009 · wk-form4_1779221004.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,501 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,666 | $6.28 | $261,612.48 |
DisclosureSEC source: 0001321402-26-000009 · wk-form4_1779221004.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,774,781 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $6.21 to $6.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,833 | $0.99 | $20,624.67 |
DisclosureSEC source: 0001321402-26-000009 · wk-form4_1779221004.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,816,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 74,872 | Not disclosed Strike: $5.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 10 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4 · derivative.exercise_date: Each Option vested in full in connection with consummation of the Merger. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 42,467 | Not disclosed Strike: $10.27 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 9 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 30,474 | Not disclosed Strike: $12.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 8 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 45,423 | Not disclosed Strike: $8.55 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 7 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 36,111 | Not disclosed Strike: $10.71 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 6 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 18,574 | Not disclosed Strike: $12.81 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 19,473 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,473 shares Expires 2029-06-27 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 16,236 | Not disclosed Strike: $8.60 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.71 | Not disclosed |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-09 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerCommon Stock | 115,857 | $14.50 | $1,679,926.50 |
DisclosureSEC source: 0001193125-26-182264 · ownership.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,834 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001321402-26-000008 · wk-form4_1776456264.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,334 Underlying: Common Stock · 20,834 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,668 | $6.29 | $261,954.22 |
DisclosureSEC source: 0001321402-26-000008 · wk-form4_1776456264.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,795,614 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $6.21 to $6.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,834 | $0.99 | $20,625.66 |
DisclosureSEC source: 0001321402-26-000008 · wk-form4_1776456264.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,837,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001321402-26-000006 · wk-form4_1773866543.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,168 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F6 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,666 | $5.84 | $243,329.44 |
DisclosureSEC source: 0001321402-26-000006 · wk-form4_1773866543.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,816,448 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.79 to $5.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,128 shares acquired under the Issuer's employee stock purchase plan on February 27, 2026. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,833 | $0.99 | $20,624.67 |
DisclosureSEC source: 0001321402-26-000006 · wk-form4_1773866543.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,856,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001610717-26-000067 · form4.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,001 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 41,666 | $6.26 | $260,620.83 |
DisclosureSEC source: 0001610717-26-000067 · form4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,836,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · price: Transaction was executed in multiple trades in prices ranging from $6.08 to $6.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 20,833 | $0.99 | $20,624.67 |
DisclosureSEC source: 0001610717-26-000067 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,877,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2 | $5.70 | $11.40 |
DisclosureSEC source: 0001610717-26-000058 · form4.xml · nonDerivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,986 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1 | $5.70 | $5.70 |
DisclosureSEC source: 0001610717-26-000058 · form4.xml · nonDerivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,988 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2 | $5.70 | $11.40 |
DisclosureSEC source: 0001610717-26-000058 · form4.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,989 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,576 | $5.71 | $31,860.15 |
DisclosureSEC source: 0001610717-26-000058 · form4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,991 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 40,401 | $5.87 | $236,951.87 |
DisclosureSEC source: 0001610717-26-000058 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,862,567 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:30 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 1,230 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001321402-26-000003 · form4-01282026_040105.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,230 Underlying: Common Stock · 1,230 shares Expires 2036-01-26 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:26 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 669,330 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001610717-26-000022 · form4.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,330 Underlying: Common Stock · 669,330 shares Expires 2036-01-23 F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:26 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 446,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000022 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,902,968 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes the purchase of 1,385 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 46,887 | $5.54 | $259,608.63 |
DisclosureSEC source: 0001610717-25-000396 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,455,363 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 01:08 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 45,687 | $5.93 | $271,001.58 |
DisclosureSEC source: 0001628280-25-041135 · wk-form4_1756170491.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,502,250 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:58 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 74,872 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000950170-25-083223 · ownership.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,872 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:58 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 20,414 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083223 · ownership.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,857 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:52 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 46,817 | $4.08 | $191,078.90 |
DisclosureSEC source: 0001628280-25-027429 · wk-form4_1747965127.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,547,937 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001628280-25-022355 · wk-form4_1746490444.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 415,834 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.